Efficacy of rFIXFc versus rIX-FP for the Treatment of Patients with Hemophilia B: Matching-Adjusted Indirect Comparison of B-LONG and PROLONG-9FP Trials-Reference-Cited by-同舟云学术

Efficacy of rFIXFc versus rIX-FP for the Treatment of Patients with Hemophilia B: Matching-Adjusted Indirect Comparison of B-LONG and PROLONG-9FP Trials

Published:2021-07 Issue: Volume:Volume 12 Page:613-621
ISSN:1179-2736
Container-title:Journal of Blood Medicine
language:en
Short-container-title:JBM

Author:

Astermark Jan,Wojciechowski Piotr^ORCID,Aballéa Samuel,Hakimi Zalmai,Nazir Jameel,Klamroth Robert^ORCID

Publisher

Informa UK Limited

Subject

Hematology

Reference26 articles.

1. Practical aspects of extended half-life products for the treatment of haemophilia

2. The benefits of prophylaxis in patients with hemophilia B

3. Optimal trough levels in haemophilia B: Raising expectations

Cited by 6 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Recombinant factor IX Fc for the treatment of hemophilia B;European Journal of Haematology;2024-02-18

2. Matching-Adjusted Indirect Comparison of Recombinant Factor IX Albumin Fusion Protein Versus Recombinant Factor IX Fc Fusion Protein for Weekly Prophylactic Treatment of Hemophilia B;Advances in Therapy;2023-12-09

3. Indirect treatment comparisons of the gene therapy etranacogene dezaparvovec versus extended half‐life factor IX therapies for severe or moderately severe haemophilia B;Haemophilia;2023-10-30

4. Recombinant factor IX Fc for major surgery in hemophilia B: factor IX plasma activity levels and effective hemostasis;Research and Practice in Thrombosis and Haemostasis;2023-08

5. Efficacy of rFIXFc versus N9-GP Prophylaxis in Patients with Hemophilia B: Matching-Adjusted Indirect Comparison of B-LONG and PARADIGM 2 Trials;Journal of Blood Medicine;2023-07